에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

Jinxin Technology Aims for 5 Million Paying Users and 100 Million RMB in Annual Revenue by 2025 Through Its Collaboration with China Mobile

NAMI

Jinxin Technology Holding Expands Partnership With China Mobile To Drive 5G New Call Innovation

Benchmark analyst Mickey Legg reiterates KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

KULR

Benchmark Reiterates Buy on KULR Tech Gr, Maintains $5 Price Target

High-rolling investors have positioned themselves bullish on Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GS often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Goldman Sachs Group. This is not a typical pattern.
The sentiment among these major traders is split, with 44% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $28,220, and 8 calls, totaling $348,291.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $490.0 to $610.0 for Goldman Sachs Group over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Goldman Sachs Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Goldman Sachs Group's significant trades, within a strike price range of $490.0 to $610.0, over the past month.
<h3>Goldman Sachs Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742305542_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.48</td>
<td>$2.2</td>
<td>$2.51</td>
<td>$570.00</td>
<td>$103.6K</td>
<td align="right">677</td>
<td>520</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.72</td>
<td>$2.38</td>
<td>$2.72</td>
<td>$570.00</td>
<td>$46.8K</td>
<td align="right">677</td>
<td>1.0K</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.88</td>
<td>$2.86</td>
<td>$2.87</td>
<td>$570.00</td>
<td>$42.8K</td>
<td align="right">677</td>
<td>1.1K</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$13.05</td>
<td>$12.05</td>
<td>$12.0</td>
<td>$545.00</td>
<td>$36.0K</td>
<td align="right">714</td>
<td>43</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$90.4</td>
<td>$85.2</td>
<td>$88.18</td>
<td>$490.00</td>
<td>$35.2K</td>
<td align="right">135</td>
<td>4</td>
</tr>
</tbody>
</table>

<h3>About Goldman Sachs Group</h3>
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
Having examined the options trading patterns of Goldman Sachs Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Goldman Sachs Group Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 43,529, the GS's price is down by -0.07%, now at $550.94. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>Expert Opinions on Goldman Sachs Group</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $689.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Goldman Sachs Group with a target price of $659. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Goldman Sachs Group with a target price of $720. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Goldman Sachs Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Behind the Scenes of Goldman Sachs Group's Latest Options Trends

Investors with a lot of money to spend have taken a bearish stance on Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BAC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Bank of America.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 66%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $442,339, and 4 are calls, for a total amount of $135,492.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $41.5 and $55.0 for Bank of America, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Bank of America options trades today is 5106.2 with a total volume of 3,432.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Bank of America's big money trades within a strike price range of $41.5 to $55.0 over the last 30 days.
<h3>Bank of America 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742305537_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.59</td>
<td>$2.53</td>
<td>$2.59</td>
<td>$43.00</td>
<td>$103.6K</td>
<td>4.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.95</td>
<td>$45.00</td>
<td>$100.7K</td>
<td>2.9K</td>
<td>755</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.95</td>
<td>$45.00</td>
<td>$98.7K</td>
<td>2.9K</td>
<td>250</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.56</td>
<td>$2.49</td>
<td>$2.56</td>
<td>$43.00</td>
<td>$88.0K</td>
<td>4.2K</td>
<td>200</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.56</td>
<td>$2.46</td>
<td>$2.56</td>
<td>$43.00</td>
<td>$51.2K</td>
<td>4.2K</td>
<td>200</td>
</tr>
</tbody>
</table>

<h3>About Bank of America</h3>
Bank of America is one of the largest financial institutions in the United States, with more than $3.2 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
Having examined the options trading patterns of Bank of America, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Bank of America</h3>
<ul>
<li>With a volume of 618,247, the price of BAC is up 0.57% at $41.67. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 28 days.</li>
</ul>
<h3>Expert Opinions on Bank of America</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $50.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Baird has upgraded their rating to Outperform and adjusted the price target to $50. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bank of America with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Spotlight on Bank of America: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bearish approach towards MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MELI usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for MercadoLibre. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 69% bearish. Among these notable options, 7 are puts, totaling $308,645, and 6 are calls, amounting to $295,537.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1650.0 to $2400.0 for MercadoLibre over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for MercadoLibre's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MercadoLibre's whale activity within a strike price range from $1650.0 to $2400.0 in the last 30 days. 
<h3>MercadoLibre 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742305532_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$101.9</td>
<td>$86.1</td>
<td>$92.59</td>
<td>$2100.00</td>
<td>$85.5K</td>
<td align="right">27</td>
<td align="right">17</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$91.9</td>
<td>$76.6</td>
<td>$81.81</td>
<td>$2100.00</td>
<td>$76.0K</td>
<td align="right">24</td>
<td align="right">8</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$126.4</td>
<td>$112.1</td>
<td>$117.73</td>
<td>$2000.00</td>
<td>$58.8K</td>
<td align="right">10</td>
<td align="right">5</td>
</tr>
<tr>
<td>MELI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$102.0</td>
<td>$85.1</td>
<td>$102.0</td>
<td>$2100.00</td>
<td>$57.6K</td>
<td align="right">27</td>
<td align="right">0</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$92.0</td>
<td>$76.0</td>
<td>$92.0</td>
<td>$2100.00</td>
<td>$51.7K</td>
<td align="right">24</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About MercadoLibre</h3>
MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
In light of the recent options history for MercadoLibre, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>MercadoLibre's Current Market Status</h3>
<ul>
<li>Trading volume stands at 4,330, with MELI's price down by -0.62%, positioned at $2093.51.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 44 days.</li>
</ul>
<h3>What Analysts Are Saying About MercadoLibre</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $2662.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on MercadoLibre with a target price of $2750. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on MercadoLibre with a target price of $2300. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on MercadoLibre, maintaining a target price of $3000. 
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on MercadoLibre with a target price of $2760. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on MercadoLibre, which currently sits at a price target of $2500. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MercadoLibre options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

MELI

MercadoLibre Options Trading: A Deep Dive into Market Sentiment

BWS Financial analyst Hamed Khorsand maintains Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Sell and maintains $6 price target.

BWS Financial Maintains Sell on Sable Offshore, Maintains $6 Price Target

Benchmark analyst Mickey Legg reiterates Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Buy and maintains $18 price target.

RIVN

Benchmark Reiterates Buy on Rivian Automotive, Maintains $18 Price Target

INDP

Indaptus Therapeutics Shares Resume Trade

Stephens &amp; Co. analyst Mason Carrico reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Equal-Weight and maintains $17 price target.

STAA

Stephens & Co. Reiterates Equal-Weight on Staar Surgical, Maintains $17 Price Target

ZOOZ Power (Nasdaq and TASE: ZOOZ), a leading provider of flywheel-based power boosters and energy management systems for enabling ultra-fast EV charging solutions, announced today the enhancement of its strategic focus with the introduction of Energy Storage Systems (ESS) and an enhanced Energy Management System (EMS) designed to lead to maximizing EV charging performance and cost efficiency, along with the expansion of its sales team.
The newly introduced Energy Storage System (ESS), in addition to ZOOZ Power's intelligent&#x2A; boosting offering, allows charging operators to significantly reduce electricity costs by storing energy during off-peak periods and deploying it during peak demand hours. This new addition to ZOOZ Power's offering of systems to manage and improve overall power delivery to clusters of ultra-fast EV chargers substantially lowers operational expenses and enhances overall cost efficiency of EV charging infrastructure.
Additionally, ZOOZ Power has upgraded its Energy Management System (EMS), improving the benefits of both the Intelligent Power Booster solution (ZOOSTER) and the new ESS offerings. The advanced EMS operates locally on-site, providing real-time management and rapid response capabilities to efficiently control energy flow, reduce power peaks, and extend battery lifecycles.
The ZOOZTER Intelligent Power Booster continues to play a vital role in ZOOZ Power's comprehensive solution, offering ultra-fast EV charging even in locations with limited grid capacity. By providing high-power bursts during charging sessions, the ZOOZTER effectively mitigates grid constraints, allowing consistent and reliable ultra-fast charging without costly infrastructure upgrades.
In conjunction with its technological advancements, ZOOZ Power is expanding its global sales team. The Company is excited to announce the appointment of Mr. Ilan Tevet as the new Vice President of Global Sales. With over 25 years of experience in global B2B sales, business development and marketing, Ilan has a proven track record of driving growth. His deep expertise will be instrumental in accelerating ZOOZ Power's planned global expansion.
Furthermore, ZOOZ Power is strengthening its worldwide sales presence by appointing new sales managers in strategic markets, including the UK, Germany, and France. Further expansions are planned in other regions to align with the growing adoption of electric vehicles.

ZOOZ

ZOOZ Power Enhances Its Strategic Focus With The Introduction Of Energy Storage Systems And An Enhanced Energy Management System Designed To Lead To Maximizing EV Charging Performance And Cost Efficiency, Along With The Expansion Of Its Sales Team

Stephens &amp; Co. analyst Mason Carrico reiterates Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) with a Overweight and maintains $3.5 price target.

AKYA

Stephens & Co. Reiterates Overweight on Akoya Biosciences, Maintains $3.5 Price Target

A sudden spike in U.S. spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44359400/bitcoin-etfs-see-record-5-5-billion-in-outflows-in-5-weeks-as-tariff-turbulence-looms">ETF inflows</a> has caused only a brief rally, with prices reversing in early Tuesday trading.
What Happened: U.S. spot Bitcoin ETFs recorded their highest daily net inflows in six weeks on Monday, totaling $274.6 million. 
This follows five consecutive weeks of net outflows amounting to $5.4 billion, according to SoSoValue <a href="https://sosovalue.xyz/zh/assets/etf">data</a>. 
Analysts attribute the shift to Bitcoin's price stabilization, institutional rebalancing and demand for lower-fee ETFs, The Block <a href="https://www.theblock.co/post/346700/us-spot-bitcoin-etfs-post-largest-daily-net-inflows-in-six-weeks-worth-274-million?utm_source=rss&amp;utm_medium=rss">reported</a>.
Fidelity's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#NASDAQ">FBTC</a>) led inflows with $127.3 million, followed by Ark/21Shares' (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>) with $88.5 million and BlackRock's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) with $42.3 million. 
Bitcoin is down 1.7% to $82,000 in Tuesday morning trading.
Analysts anticipate continued fluctuations, with institutional rebalancing potentially driving further inflows or outflows.
As the quarter-end approaches, investors are closely monitoring positioning shifts.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363871/peter-schiff-slams-bitcoin-etfs-calls-selling-gold-for-btc-worst-timed-trade-in-history">Peter Schiff Slams Bitcoin ETFs, Calls Selling Gold For BTC &#8216;Worst-Timed Trade In History&#8217;</a>
What's Next: Crypto trader Moustache said he is watching this week closely as the FOMC meeting and other key events unfold. 
He predicts a significant price increase, with Bitcoin's consolidation below the daily SMA200 (simple moving average) line indicating bullish momentum.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> I&#39;m really looking forward to this week. Very important events + FOMC and <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> consolidating below the daily SMA200 line (which is actually bullish). I wouldn&#39;t be surprised if we see a big green candle soon. <a href="https://t.co/6EDP3otxX0">pic.twitter.com/6EDP3otxX0</a>
&mdash; 
</blockquote></div></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

Bitcoin Meanders Around $82,000 As ETFs Net $275 Million In Inflows

Stephens &amp; Co. analyst Andrew Terrell reiterates Coastal Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCB#NASDAQ">CCB</a>) with a Overweight and maintains $100 price target.

Stephens & Co. Reiterates Overweight on Coastal Finl, Maintains $100 Price Target

D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $18 price target.

COYA

D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target

Stephens &amp; Co. analyst Mike Scialla upgrades CNX Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) from Equal-Weight to Overweight and raises the price target from $35 to $48.

Upgrades

Stephens & Co. Upgrades CNX Resources to Overweight, Raises Price Target to $48

ndaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 56.4%

Wells Fargo analyst Sam Reid maintains Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a Equal-Weight and lowers the price target from $130 to $125.

Wells Fargo Maintains Equal-Weight on Lennar, Lowers Price Target to $125

Strategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are trading lower Tuesday after the company announced an offering of 5 million shares of its Series A Perpetual Strife Preferred Stock in <a href="https://www.benzinga.com/pressreleases/25/03/b44374511/strategy-announces-proposed-strf-perpetual-preferred-stock-offering">a public offering.</a>
Strategy previously said it plans to sell its Perpetual Strife Preferred Stock over an extended period of time. The preferred stock will accumulate cumulative dividends at a fixed rate of 10% per annum.
Strategy has the right to redeem its preferred stock for cash if certain conditions are met. The liquidation preference of the perpetual strife preferred stock is initially set at&nbsp;$100&nbsp;per share. 
Strategy said it intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). The company announced plans in October 2024 to raise <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41818982/will-microstrategys-42-billion-bitcoin-bet-boost-mstr-stock-further">$42 billion</a> over the next three years in an effort to keep stacking Bitcoin.
As of March 9, Strategy held an aggregate of approximately 499,096 Bitcoin, acquired at an average purchase price of approximately $66,357 per coin.
MSTR Price Action: <a href="http://benzinga.com/quote/mstr">Strategy shares</a> were down 4.17% at $282.00 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44374550/bernstein-targets-310-for-coinbase-stock-cites-lifting-regulatory-dark-cloud">Bernstein Targets $310 For Coinbase Stock, Cites Lifting &#8216;Regulatory Dark Cloud&#8217;</a></li>
</ul>
Photo: Shutterstock.

MSTR

Strategy Stock Is Sliding Tuesday: What's Going On?

Stephens &amp; Co. analyst Mike Scialla upgrades EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) from Equal-Weight to Overweight and raises the price target from $41 to $59.

Stephens & Co. Upgrades EQT to Overweight, Raises Price Target to $59

<ul>
<li>First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremities</li>
<li>Protocol involves one or two PDT treatments using 1-3 tubes of Ameluz&#xAE; or vehicle gel over a surface area of up to 240 cm2
<ul>
<li>Treatment phase expected to be complete by Q3 2025</li>
</ul>
</li>
</ul>

Biotech

General

BFRI

Biofrontera Completes Patient Enrollment Of Phase 3 Study Of Ameluz Topical Gel, 10% For Actinic Keratoses On Extremities\

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Truist Securities

Leerink Partners

HC Wainwright & Co.

BMO Capital

Morgan Stanley

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요?
1. 테라다인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 <a href="https://www.benzinga.com//node/44236516" target="_blank" rel="noreferrer noopener">비공개 금액에 인수하기로 합의</a>했다. 애널리스트들은 이 회사의 <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 하향 조정</a>했다.
2. 트레이드 데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>)의 주가가 16.90% 급락했다. 이는 아마도 관세와 무역 정책으로 인한 경제적 우려 때문이다.
3. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주가가 15.79% 하락했다. 이는 <a href="https://www.benzinga.com//node/44287858" target="_blank" rel="noreferrer noopener">비트코인이 관세 불확실성으로 인해 하락</a>했기 때문이다.
4. 세일포인트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>)의 주가가 15.19% 하락했다.
5. 젠맙(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>)의 주가가 15.04% 하락했다. 이는 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)이 HexaBody-CD38에 대한 전 세계 개발, 제조 및 상용화 라이선스를 받을 옵션을 행사하지 않기로 결정한 후 발생한 일이다. 젠맙은 <a href="https://www.benzinga.com//node/44221409" target="_blank" rel="noreferrer noopener">추가 임상 개발을 진행하지 않기로</a> 했다.
6. 인터랙티브 브로커스 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>)의 주가가 12.52% 하락했다. 이는 아마도 관세 불확실성으로 인한 전반적인 시장 우려 때문일 것이다.
7. 델타 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)의 주가가 12.26% 급락했다. 회사가 첫 분기 <a href="https://www.benzinga.com//node/44244750" target="_blank" rel="noreferrer noopener">매출과 이익 가이던스를 하향 조정</a>했기 때문이다.
8. 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)의 주가가 12.16% 하락했다. 이는 회사가 2분기 및 2025 회계연도 조정 EPS 가이던스를 발표했으며, 그 중간값이 예상보다 낮았기 때문이다. 여러 애널리스트들도 <a href="https://www.benzinga.com//node/44302063" target="_blank" rel="noreferrer noopener">가격 전망을 수정</a>했다.
9. 익스피디아 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)의 주가가 12.05% 하락했다. 이는 여행 관련 주식들이 <a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">전반적인 매도세</a>로 인해 하락한 후 발생한 일이다. <a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">델타 항공이</a><a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener"> 가이던스 하향 조정</a>을 발표했다.
10. 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 주가가 11.66% 하락했다. 회사는 <a href="https://www.benzinga.com//node/44252567" target="_blank" rel="noreferrer noopener">2월 운영 데이터를 발표</a>했다.
11. 유나이티드 항공 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)의 주가가 11.11% 하락했다. 이는 BofA 증권과 바클레이즈가 주식에 대한 <a href="https://www.benzinga.com/quote/ual/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 가격 전망을 하향 조정</a>했기 때문다.
12. 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)의 주가가 10.70% 하락했다. 이는 지속적인 관세 불확실성으로 인한 전반적인 시장 약세 때문이다.
사진 제공: Useacoin, Shutterstock
다음 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%B1%EB%9F%AC%EB%B9%88-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0-%EC%9D%B8%ED%85%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EA%B8%89%EB%93%B1%ED%95%9C/" target="_blank" rel="noopener">앱러빈, 슈퍼 마이크로 컴퓨터, 인텔 등 지난주 급등한 대형주 10종목 (3월 10일-3월 14일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Genmab

뉴스

에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

일요일, 3월 16, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌